Capricor Therapeutics (CAPR) Equity Average (2016 - 2025)
Historic Equity Average for Capricor Therapeutics (CAPR) over the last 15 years, with Q3 2025 value amounting to $94.4 million.
- Capricor Therapeutics' Equity Average rose 13674.41% to $94.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $94.4 million, marking a year-over-year increase of 13674.41%. This contributed to the annual value of $84.0 million for FY2024, which is 38873.43% up from last year.
- Latest data reveals that Capricor Therapeutics reported Equity Average of $94.4 million as of Q3 2025, which was up 13674.41% from $116.3 million recorded in Q2 2025.
- In the past 5 years, Capricor Therapeutics' Equity Average ranged from a high of $136.6 million in Q1 2025 and a low of $471753.5 during Q3 2023
- Its 5-year average for Equity Average is $40.6 million, with a median of $28.0 million in 2022.
- In the last 5 years, Capricor Therapeutics' Equity Average tumbled by 9723.76% in 2023 and then skyrocketed by 835433.74% in 2024.
- Quarter analysis of 5 years shows Capricor Therapeutics' Equity Average stood at $34.1 million in 2021, then tumbled by 60.04% to $13.6 million in 2022, then dropped by 23.51% to $10.4 million in 2023, then soared by 926.85% to $106.9 million in 2024, then dropped by 11.64% to $94.4 million in 2025.
- Its last three reported values are $94.4 million in Q3 2025, $116.3 million for Q2 2025, and $136.6 million during Q1 2025.